Since insensitivity of breast cancers to EGFR targeted therapies presents a clinical challenge, it would be worthwhile to determine if gefitinib in combination with HCQ is broadly effective in the gefitinib-insensitive phenotype. This evidence concerns the gene EGFR and breast carcinoma.